Biopharma Informatic, Llc

Houston, Texas 77089

9 studies enrolling now · 71 studies all time

What they study most

Active Systemic Lupus Erythematosus, Alcohol Use Disorder, Arthritis, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Atopic Dermatitis, Autoimmune Diseases, Cardiovascular Diseases, Cardiovascular Risk, Celiac Disease, Chronic Gout, Chronic Kidney Disease

Studies at this site

• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee — Recruiting now
• A Study of Brenipatide in Participants With Opioid Use Disorder — Recruiting now
• Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease — Recruiting now
• A Study of Brenipatide in Participants With Alcohol Use Disorder — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — Recruiting now
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Recruiting now
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy — Completed
• A Study of Baricitinib in Participants With Rheumatoid Arthritis — Completed
• ABTECT - Maintenance — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection — Stopped early
• A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) — Completed
• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Running, not enrolling
• A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) — Completed
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain — Stopped early
• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis — Stopped early
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities — Completed
• Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes — Paused
• A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection — Stopped early
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — Running, not enrolling
• A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes — Completed
• A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis — Completed
• A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet — Completed
• Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease — Completed
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections — Completed
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) — Stopped early
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia — Completed
• Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus — Stopped early